Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate Midazolam in Patients With ALK-Positive or ROS1-Positive Solid Tumors

Trial Profile

A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate Midazolam in Patients With ALK-Positive or ROS1-Positive Solid Tumors

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Feb 2019

At a glance

  • Drugs Brigatinib (Primary) ; Midazolam
  • Indications Non-small cell lung cancer; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors ARIAD Pharmaceuticals; Takeda
  • Most Recent Events

    • 05 Feb 2019 Planned initiation date changed from 10 Jan 2019 to 7 Feb 2019.
    • 06 Dec 2018 Planned initiation date changed from 29 Oct 2018 to 10 Jan 2019.
    • 03 May 2018 Planned initiation date changed from 20 Apr 2018 to 29 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top